Financials in USD. Standardized financial statements.
A compact view of how Sihuan Pharmaceutical Holdings Group Ltd. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $2.55B | $1.90B | $1.86B | $2.18B | $3.04B | $2.46B | $2.88B | $2.92B | $2.75B | $3.19B |
| Revenue Growth? | +34.2% | +2.2% | -14.7% | -28.2% | +23.3% | -14.4% | -1.3% | +6.2% | -13.8% | 0.0% |
| Cost of Revenue? | $795.09M | $659.40M | $564.89M | $693.61M | $607.90M | $549.78M | $588.99M | $538.32M | $758.96M | $996.75M |
| Gross Profit? | $1.76B | $1.24B | $1.30B | $1.49B | $2.43B | $1.91B | $2.29B | $2.38B | $1.99B | $2.19B |
| Gross Margin? | +68.8% | +65.3% | +69.6% | +68.2% | +80.0% | +77.7% | +79.5% | +81.5% | +72.4% | +68.7% |
| Operating Expenses? | $1.37B | $1.38B | $1.13B | $3.32B | $1.66B | $1.13B | $4.88B | $525.42M | $355.21M | $147.70M |
| Operating Income? | $382.35M | -$138.13M | $161.70M | -$1.83B | $771.95M | $787.13M | $1.39B | $1.72B | $1.47B | $1.94B |
| EBITDA? | $432.35M | $105.07M | $334.31M | -$1.54B | $931.69M | $714.06M | -$2.06B | $1.92B | $1.68B | $2.18B |
| Income Before Tax | $406.39M | -$428.29M | -$161.26M | -$2.12B | $496.01M | $765.84M | -$2.42B | $2.01B | $1.73B | $2.15B |
| Income Tax Expense | $225.77M | $43.26M | $96.43M | $196.79M | $253.12M | $219.04M | $290.39M | $332.80M | $250.17M | $472.73M |
| Net Income? | $175.06M | -$216.66M | -$54.02M | -$1.91B | $416.51M | $473.38M | -$2.75B | $1.62B | $1.45B | $1.71B |
| EPS? | $0.02 | $-0.02 | $-0.01 | $-0.21 | $0.04 | $0.05 | $-0.29 | $0.17 | $0.15 | $0.17 |
| Diluted EPS? | $0.02 | $-0.02 | $-0.01 | $-0.21 | $0.04 | $0.05 | $-0.29 | $0.17 | $0.15 | $0.17 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality